Targeting a specific receptor to improve treatment for lung fibrosis
Targeting Fibroblast Discoidin Domain Receptor 2 for Immunotherapy to Pulmonary Fibrosis
This study is looking at a protein called DDR2 that might play a big role in worsening lung scarring in people with progressive pulmonary fibrosis, and by focusing on this protein, researchers hope to create better treatments that could help you breathe easier and feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10983754 on NIH RePORTER |
What this research studies
This research focuses on improving therapies for progressive pulmonary fibrosis, a serious lung condition. It investigates the role of discoidin domain receptor 2 (DDR2), a specific protein found in fibroblasts, which may be crucial in driving fibrosis. By targeting DDR2, the research aims to develop more effective treatments that can specifically inhibit the pathways leading to lung scarring. Patients may benefit from a more tailored approach to therapy that could lead to better outcomes than current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with progressive pulmonary fibrosis or related lung conditions.
Not a fit: Patients with non-fibrotic lung diseases or those who do not have a diagnosis of pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting specific receptors for treating fibrosis, indicating potential success for this approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Kim, Kevin Keewoun — University of Michigan at Ann Arbor
- Study coordinator: Kim, Kevin Keewoun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.